Zenabis Global (TSX:ZENA) generated cultivation output in May of 908 kg of dried cannabis, which represents a 35.1% outperformance relative to design capacity.
Canopy Growth (TSX:WEED; NYSE:CGC) reported net revenue of $226.3-million for the fiscal year ended March 31, 2019, an increase of 191%, compared with $77.9-million a year earlier.
ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that the FDA provided positive feedback to the company’s pre-IND meeting regarding CRV431 for the treatment of non-alcoholic steatohepatitis (NASH).
BeyondSpring (NASDAQ:BYSI) will join the FTSE Russell 3000 Index when markets open on July 1, according to a preliminary list of additions. Membership in the Russell 3000 Index, which remains in place for one year...
Akari Therapeutics (NASDAQ:AKTX) reported positive data from the first part of its Phase 1/2 study of topical nomacopan in moderate to severe atopic keratoconjunctivitis (AKC).
The FDA has accepted Melinta Therapeutics’ (NASDAQ:MLNT) supplemental NDA (sNDA) for BAXELDA for the treatment of community-acquired bacterial pneumonia (CABP).
Shareholders of Canopy Growth (TSX:WEED; NYSE:CGC) and Acreage Holdings (CSE:ACGR; OTC:ACRGF; FSE:0ZV) at separate meetings overwhelmingly approved the proposed acquisition of Acreage by Canopy through a share exchange.
G1 Therapeutics (NASDAQ:GTHX) reported preliminary overall survival results from a Phase 2 trial of trilaciclib in women with metastatic triple-negative breast cancer (mTNBC).
Eiger BioPharmaceuticals’ (NASDAQ:EIGR) avexitide received FDA breakthrough therapy designation for the treatment of post-bariatric hypoglycemia (PBH).
PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported initial results from its Phase 2a trial assessing PB2452’s ability to reverse the effects of the antiplatelet drug, ticagrelor, in subjects 50-to-80 years of age.
Closely-held Lutronic Vision’s R:GEN laser has treated its first central serous chorioretinopathy (CSC) patient at Seoul National University Hospital (SNUH).
Closely-held Ocutrx Vision Technologies reported that its augmented reality (AR) glasses significantly improved functional vision compared with standard near correction glasses, or no correction, in subjects with...
Karyopharm Therapeutics (NASDAQ:KPTI) provided new and updated data from its Phase 1b/2 study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma (MM) therapies.
Kura Oncology (NASDAQ:KURA) provided updated interim data from its Phase 2 trial of tipifarnib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Progenics Pharmaceuticals (NASDAQ:PGNX) dosed the first patient in a Phase 2 clinical study evaluating I-131 1095 radiotherapy for the treatment of metastatic castration resistant prostate cancer (mCRPC).
NuCana (NASDAQ:NCNA) received the FDA’s orphan drug designation for acelarin, a nucleoside analog of gemcitabine, for the treatment of biliary tract cancer.
Nuvectra (NASDAQ:NVTR) filed a regulatory submission with the FDA for conditional approval of full-body magnetic resonance (MR) imaging in patients implanted with the company’s Algovita spinal cord stimulation (SCS)...